Pay in 4 interest-free payments of $5.21 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Quick Comparison: Eloralintide vs Retatrutide Attribute Eloralintide Retatrutide Developer Eli Lilly Eli Lilly Class Selective amylin receptor agonist (LY-3841136 class) Triple agonist (LY3437943) Receptors targeted Amylin receptor only GIP + GLP-1 + glucagon Administration in trials Once weekly Once weekly, subcutaneous Phase 2 population 263 adults with obesity or overweight plus at least one obesity-related comorbidity, without type 2 diabetes 338 participants with obesity or overweight with weight-related conditions, excluding type 2 diabetes Phase 2 duration 48 weeks 48 weeks Reported mean weight reduction 9.5%-20.1% across arms vs 0.4% placebo (~20.1% at 9 mg) Up to 24.2% (~26.2 kg / ~58 lb) at the highest dose Tolerability signal Mild-to-moderate GI events
The dose isn't the first variable to adjust
Complete PCOS Treatment Approach Oana Health goes beyond weight management by combining GLP-1 medications with Metformin to address insulin resistance, hormonal imbalances, and other PCOS symptoms
Available at: Jastreboff AM, Aronne LJ, Ahmad NN, et al
These are often temporary
